Variables | Total (N = 87) | Definitive therapy without anaerobic coverage (N = 24) | Definitive therapy with anaerobic coverage (N = 63) | p value |
---|---|---|---|---|
Age (mean) | 73.4 ± 13.9 | 71.5 ± 14.2 | 74.2 ± 13.9 | 0.419 |
Male sex | 65(74.7) | 18(75) | 47 (74.6) | 0.970 |
Underlying disease | ||||
Diabetes mellitus | 31(35.6) | 8(33.3) | 23(36.5) | 0.782 |
Congestive heart failure | 30(34.5) | 3(12.5) | 17(27.0) | 0.151 |
Liver cirrhosis | 4(4.6) | 3(12.5) | 1(1.6) | 0.062 |
Chronic obstructive pulmonary diseases | 10(11.5) | 1(4.2) | 9(14.3) | 0.186 |
Chronic renal failure | 68(78.2) | 14(58.3) | 54(85.7) | 0.006 |
Malignancy | 35(40.2) | 9(37.5) | 26(41.3) | 0.749 |
Healthcare-associated bacteremia | 38(43.7) | 8(33.3) | 30(47.6) | 0.230 |
Microbiology | ||||
E.coli | 48(55.2) | 16(66.7) | 32(51.6) | 0.207 |
K. pneumoniae | 20(23.0) | 2(8.7) | 18(28.6) | 0.053 |
Othersa | 28(32.2) | 6(25.0) | 22(34.9) | 0.38 |
Biliary abnormalities | ||||
Malignant obstruction | 31(35.6) | 7(29.3) | 24(38.1) | 0.437 |
Benign stricture | 2(2.3) | 0(0.0) | 2(3.2) | 1.000 |
Choledocholithiasis | 52(59.8) | 15(62.5) | 37(58.7) | 0.749 |
Unknown | 2(2.3) | 2(8.3) | 0(0.0) | 0.074 |
Pitt bacteremia score(mean) | 1.2 ± 1.5 | 1.5 ± 1.8 | 1.1 ± 1.3 | 0.270 |
Biliary drainageb | 73(83.9) | 20(83.3) | 53(84.1) | 0.928 |
Appropriate empirical therapy | 65(74.7) | 18(75.0) | 47(74.6) | 0.970 |
Empirical therapy with anaerobic coverage | 68(78.2) | 12(50) | 56(88.9) | < 0.001 |
Clinical outcome | ||||
Clinical improvement | 70(80.5) | 20(83.3) | 50(79.4) | 0.677 |
Treatment failure | 17(19.5) | 4(16.7) | 13(20.6) | 0.677 |
Relapse | 13(14.9) | 3(12.5) | 10(15.9) | 0.693 |
28-day mortality | 4(4.6) | 1(4.2) | 3(4.8) | 1.000 |
Duration (days) of anaerobic coverage | 9.1 ± 6.0 | 2.2 ± 1.8 | 11.8 ± 4.7 | < 0.001 |
Total duration (days) of antibiotic use | 13.2 ± 5.2 | 13.1 ± 5.7 | 13.2 ± 5.0 | 0.913 |